𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Selective adenosine A2A receptor antagonists

✍ Scribed by Ennio Ongini; Angela Monopoli; Barbara Cacciari; Pier Giovanni Baraldi


Book ID
114018885
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
87 KB
Volume
56
Category
Article
ISSN
0014-827X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


ChemInform Abstract: Selective Adenosine
✍ Ennio Ongini; Angela Monopoli; Barbara Cacciari; Pier Giovanni Baraldi πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons βš– 29 KB πŸ‘ 2 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a β€œFull Text” option. The original article is trackable v

SCH 58261: A selective A2A adenosine rec
✍ Ennio Ongini πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 173 KB πŸ‘ 1 views

The recent discovery of selective antagonists for the A 2A adenosine receptors has been of great help to further research in this field. One compound, SCH 58261, 5-amino-7-(Ξ²-phenylethyl)-2-(8furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, is playing a key part in a variety of studies. This r

Comparative molecular field analysis (Co
✍ Pier Giovanni Baraldi; Pier Andrea Borea; Manuela Bergonzoni; Barbara Cacciari; πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 304 KB πŸ‘ 2 views

Selective and potent antagonists for the A 2A adenosine receptors have been described recently. The most potent compounds have a triazolo-pyrimidine structure, whereas 8-styryl-xanthines usually possess lower affinity at the A 2A receptor. We have examined the quantitative structure activity relatio

A2A-selective adenosine receptor antagon
✍ Christa E. MΓΌller; Roland Sauer; Yuris Maurinsh; Rosa Huertas; Friederike FΓΌlle; πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 214 KB πŸ‘ 2 views

A 2A adenosine receptor (AR) antagonists are promising new drugs for the treatment of Parkinson's disease. Further potential therapeutic indications for A 2A AR antagonists include dementias, ischemias, and pain. Potent, selective A 2A AR antagonists have been developed, but their generally low wate